Title : The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment.

Pub. Date : 2021 Jul

PMID : 33970400






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment. Irinotecan tumor protein p53 Homo sapiens
2 OBJECTIVE: In our study, we evaluated the role of p53 expression in patients with RAS/BRAF wild-type metastatic colorectal cancer (mCRC) receiving irinotecan/cetuximab in an exploratory and a validation cohort. Irinotecan tumor protein p53 Homo sapiens
3 PATIENTS AND METHODS: p53 expression was analysed in patients with RAS/BRAF wild-type mCRC receiving second-line or third-line irinotecan/cetuximab. Irinotecan tumor protein p53 Homo sapiens